Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
XBIO 
Xenetic Biosciences Inc (XBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: XBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $40
1 Year Target Price $40
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.18% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.59M USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 1 | Beta 2.44 | 52 Weeks Range 2.20 - 13.93 | Updated Date 10/17/2025 |
52 Weeks Range 2.20 - 13.93 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -126.03% | Operating Margin (TTM) -122.8% |
Management Effectiveness
Return on Assets (TTM) -28.37% | Return on Equity (TTM) -51.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 294978 | Price to Sales(TTM) 3.92 |
Enterprise Value 294978 | Price to Sales(TTM) 3.92 | ||
Enterprise Value to Revenue 0.12 | Enterprise Value to EBITDA 1.03 | Shares Outstanding 2277139 | Shares Floating 1182805 |
Shares Outstanding 2277139 | Shares Floating 1182805 | ||
Percent Insiders 12.9 | Percent Institutions 3.12 |
Upturn AI SWOT
Xenetic Biosciences Inc
Company Overview
History and Background
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on the development of innovative therapeutics and novel platform technologies for the treatment of genetically defined diseases. Founded to develop advanced drug delivery and gene therapy systems, it has evolved over time.
Core Business Areas
- Onco Histology: Focuses on the development of personalized cancer therapies based on individual patient tumor profiles using the company's Onco Histology technology.
- XbioPlatform: Concentrates on the company's proprietary platform technology designed to improve the delivery and efficacy of therapeutic agents.
Leadership and Structure
The leadership team typically consists of a CEO, CFO, and other executives overseeing various departments. Organizational structure is hierarchical with distinct functional areas.
Top Products and Market Share
Key Offerings
- Onco Histology: A personalized cancer therapy approach, market share information is not publicly available. Competitors include companies offering personalized medicine solutions based on genomics and proteomics, such as Foundation Medicine (RHHBY) and Caris Life Sciences (private).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements.
Positioning
Xenetic Biosciences focuses on niche markets within personalized cancer therapy and advanced drug delivery systems. Its competitive advantage lies in its proprietary technology platforms.
Total Addressable Market (TAM)
TAM for personalized cancer therapies is estimated in the billions of dollars. Xenetic Biosciences' positioning allows it to capture a segment of this market through its focused approach.
Upturn SWOT Analysis
Strengths
- Proprietary Technology Platforms
- Focus on Personalized Medicine
- Experienced Management Team
Weaknesses
- Limited Financial Resources
- Dependence on Clinical Trial Outcomes
- Small Market Capitalization
Opportunities
- Partnerships and Collaborations
- Expansion into New Therapeutic Areas
- Positive Clinical Trial Results
Threats
- Competition from Larger Pharmaceutical Companies
- Regulatory Hurdles
- Clinical Trial Failures
Competitors and Market Share
Key Competitors
- RHHBY
- MRNA
- LLY
Competitive Landscape
Xenetic Biosciences is a smaller player in a competitive landscape dominated by larger pharmaceutical companies. Its advantages lie in its specialized technologies, but it faces challenges due to limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on clinical trial progress and partnership agreements.
Future Projections: Future growth depends on the success of its clinical trials and commercialization efforts. Analyst estimates vary.
Recent Initiatives: Recent initiatives may include advancing clinical trials, securing partnerships, and expanding its intellectual property portfolio.
Summary
Xenetic Biosciences is a small biopharmaceutical company with promising technology platforms but faces financial constraints and competition. Its success hinges on positive clinical trial outcomes and strategic partnerships. The company must manage its resources carefully and navigate regulatory hurdles effectively to achieve its growth objectives. Clinical trial failures remain a key risk. The company is highly speculative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xenetic Biosciences Inc
Exchange NASDAQ | Headquaters Framingham, MA, United States | ||
IPO Launch date 2014-06-30 | CFO, COO, Interim CEO & Corporate Secretary Mr. James F. Parslow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.xeneticbio.com |
Full time employees 2 | Website https://www.xeneticbio.com | ||
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.